Pioneering Medical Innovations
Ocular reported Q2 2026 results, confirming the AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following a positive Type C meeting with the FDA.
Imperative Care launched the Ikon 24 Pro Guidewire, enhancing the Zoom Stroke System to support more efficient stroke procedures.
A new analysis of the SYMPHONY-PE Trial suggests early thrombectomy may improve key measures of heart recovery in intermediate-risk pulmonary embolism patients.
Jay Martin was appointed Chief Commercial Officer of Imperative Care.
Ocular reported Q1 2026 results, with a cash balance of $666.7 million and expected runway into 2028, following the positive SOL-1 readout.
Ocular announced a June 17 Investor Day in New York featuring company leadership and prominent retinal disease experts.
Axtria acquired Conexus Solutions, a life sciences technology and managed services partner specializing in CRM transformation across the Veeva and Salesforce ecosystems, marking Axtria’s entry into end-to-end CRM.
Imperative Care initiated the ADAPT 2.0 study evaluating an advanced clinical technique designed to simplify acute ischemic stroke treatment.
Axtria earned Frost & Sullivan’s 2025 Global Company of the Year recognition in pharma commercial solutions, the market research firm’s highest honor.
The company initiated the CLEAR-IT clinical study targeting gaps in clinical standards for peripheral thromboembolism.